Genmab (GMAB) 6-K notes capital increase from employee warrants

Rhea-AI Filing Summary

Genmab A/S filed a Form 6-K as a foreign private issuer for November 2025. The filing attaches a company announcement dated November 18, 2025 describing a capital increase in Genmab resulting from the exercise of employee warrants.

The Form 6-K is expressly incorporated by reference into Genmab’s existing Form S-8 registration statements, making this capital increase disclosure part of those employee equity compensation-related registrations.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated November 18, 2025: Capital Increase in Genmab as a Result of Employee Warrant Exercise

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: NOVEMBER 18, 2025

FAQ

What did Genmab (GMAB) file in this document?

Genmab A/S filed a Form 6-K as a foreign private issuer for the month of November 2025 under the Securities Exchange Act of 1934.

What corporate action is highlighted in Genmab's November 2025 Form 6-K?

The filing highlights a capital increase in Genmab that occurred as a result of employee warrant exercises, as described in the attached company announcement dated November 18, 2025.

How is this Genmab 6-K related to the company’s Form S-8 registrations?

The Form 6-K is stated to be incorporated by reference into Genmab A/S’s Form S-8 registration statements (File Nos. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876), becoming part of those filings from the date it is filed.

What is included as Exhibit 99.1 in this Genmab 6-K filing?

Exhibit 99.1 is a Company Announcement dated November 18, 2025 titled “Capital Increase in Genmab as a Result of Employee Warrant Exercise.”

Who signed the Genmab November 2025 Form 6-K?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano, who is identified as Executive Vice President & Chief Financial Officer.

Why does Genmab use Form 6-K for this capital increase disclosure?

As a foreign private issuer, Genmab uses Form 6-K to furnish information such as the employee warrant-related capital increase to the U.S. market and to integrate that information into its existing Form S-8 registration statements.